GLUCOSE, GESTATIONAL SCREEN (50G)-135 CUTOFF Biomarker

Overview

This test measures the blood glucose level 1 hour after a 50 gram oral glucose load used to screen for gestational diabetes mellitus (GDM) in pregnancy. It evaluates how effectively maternal metabolism handles a standardized glucose challenge, reflecting maternal glucose tolerance during mid-pregnancy. With a 135 mg/dL cutoff, results below 135 mg/dL are considered negative, while 135 mg/dL or higher triggers a full diagnostic oral glucose tolerance test (OGTT) to confirm or exclude GDM. Screening in this range aims to balance detection of GDM against false positives and is widely used in the standard “two-step” GDM screening strategy recommended by major organizations. Identifying abnormal values helps prevent adverse outcomes such as fetal overgrowth, hypertensive disorders, and birth complications by allowing timely management of GDM.

Clinical Use Cases

Screening for gestational diabetes mellitus in pregnant individuals, typically at 24 to 28 weeks’ gestation, as part of the two-step approach (screening 50 g test followed by 100 g diagnostic OGTT if abnormal).
Early pregnancy screening for high-risk individuals (for example, obesity, prior GDM, strong family history) using the same 50 g 1-hour test, with ≥135 mg/dL often used as a positive screen to prompt an early diagnostic OGTT.
Risk stratification for adverse perinatal outcomes (such as macrosomia, cesarean birth, neonatal hypoglycemia) based on the degree of elevation of the 1-hour value, even when below traditional diagnostic thresholds.
Research into optimal screening thresholds (130, 135, 140 mg/dL) to balance sensitivity and specificity for GDM and to evaluate relationships between screening values and pregnancy outcomes.

Specimen Types

Venous blood (plasma or serum) collected 1 hour after ingestion of a 50 g oral glucose solution.

Measurement Methods

Automated plasma glucose assays (typically enzymatic methods such as hexokinase or glucose oxidase) performed on venous blood samples in a clinical laboratory.
Measurement is usually reported in mg/dL (or mmol/L) and interpreted against the chosen institutional cutoff (for example, 135 mg/dL).

Test Preparation and Influencing Factors

Fasting requirements: Fasting is generally not required for the 50 g 1-hour glucose challenge test; the test may be performed regardless of the last meal.
Timing in pregnancy: Standard screening is performed between 24 and 28 weeks’ gestation; some protocols repeat or perform earlier testing in high-risk patients.
Glucose dose and timing: The patient drinks a solution containing exactly 50 g of glucose, and blood is drawn precisely 1 hour after ingestion; deviations in timing can affect results.
Diet and recent intake: Extremely large or small carbohydrate intake immediately before the test, vomiting, or incomplete ingestion of the 50 g solution may influence the measured glucose level. This is generally managed by adhering to the test protocol and repeating the test if intake was incomplete.
Medications: Drugs that alter glucose metabolism (for example, corticosteroids, beta-agonists, some antipsychotics) can increase glucose levels and may influence results; medication review is typically part of clinical interpretation.[This point is consistent with general clinical practice and inferred from standard pharmacologic effects, as most guidelines do not list exhaustive drug-specific effects.]
Physiologic conditions: Preexisting diabetes, impaired glucose tolerance, acute illness, or stress can elevate the 1-hour value and may prompt earlier or modified testing approaches.
Institutional cutoff choice: Different practices may choose 130, 135, or 140 mg/dL as the screening threshold, which directly affects whether a given value (for example, 135 mg/dL) is considered positive or negative.